Phd in BIOCHEMISTRY

email: fabio.didomenico@uniroma1.it
phone: 06 49910900
building: CU027
room: 314

SUMMARY OF SCIENTIFIC ACHIEVEMENTS
(August 2023, from Scopus)

Papers: 106
Book chapters: 5
Total Impact factor: ≈ 490
Total Citations: 10402
H-index: 45

EDUCATION AND TRAINING

2009. PhD in Biochemical Sciences from Sapienza University of Rome
2005. University graduation in Biological Sciences from Sapienza University of Rome

WORK EXPERIENCE

2021 – present Full Professor position at the Department of Biochemical Sciences of Sapienza University of Rome
2015 – 2021. Associate Professor position at the Department of Biochemical Sciences of Sapienza University of Rome
2010 – 2015 Researcher (Assistant Professor) position at the Department of Biochemical Sciences of Sapienza University of Rome
2009 – 2010 Post-doctoral fellows (from Istituto Pasteur – Fondazione Cenci Bolognetti) at the Department of Chemistry of the University of Kentucky
2007 – 2008 PhD foreign student at the Department of Chemistry of the University of Kentucky
2005 – 2008 PhD student at the Department of Biochemical Sciences of Sapienza University of Rome
RESEARCH ACTIVITIES
Keywords: Alzheimer disease, Down syndrome, proteomics, oxidative stress, neurodegeneration, protein homeostasis
Personal Statement: My research is currently focused on understanding the role of defective proteostasis in the development of Alzheimer’s-like dementia in order to propose novel effective therapeutic approaches that might ameliorate cognitive decline. Starting in 2005, I dedicated my research on the studies of oxidative stress role in the development of neurodegenerative disease. Thanks to my experience at University of Kentucky in the laboratory of prof. D. Allan Butterfield I have been involved in the setting of proteomics approaches comprising redox proteomics. Through these use of techniques, my following research projects contributed to highlight the role of increased oxidative stress and dysfunctional protein degradation systems in the pathogenesis and progression of Alzheimer Disease-like dementia. Indeed, we demonstrated that the oxidative modification (carbonylation, protein bound HNE and nitration) of proteins, belonging to different degradation systems (proteasome and autophagy) impairs their functionality and contributes to the progression of the neurodegenerative process. Therefore, collected data postulated that aberrant proteostasis, observed in both Alzheimer’s and Down syndrome patients, is strictly associated with the increase of oxidative damage as result of compromised antioxidant response and faulty protein degradative systems. Recent studies revealed that chronic induction of the unfolded protein response has a prominent role in the development of AD-like dementia in DS brain. Indeed, the pharmacological rescue of UPR function leads to the reduction in neuropathological hallmarks and to decrease in protein oxidation in a mechanism involving the Nrf2 antioxidant response. The results obtained led to the publication of several articles on peer-reviewed journals and based on these we started to test a number of compounds for the treatment and prevention of cognitive decline in Down syndrome mice.
Research Interests:
• Role of oxidative stress and protein oxidation in Alzheimer disease, Parkinson disease and Down syndrome.
• Role of protein Glycosylation (N-Gly and O-Gly) in the development and progression of Alzheimer Disease
• Role of “Heat shock response” during the progression of Mild Cognitive Impairment to Alzheimer disease.
• Study of molecular mechanisms controlled by STAT3 involved in ischemia/reperfusion neurodegenerative process.
• Analysis of the involvement of mutated LRRK2 and tau crosstalk in the development of Parkinson disease.
• Analysis of CSF and plasma from AD and MCI patients in search of diagnostic biomarker.
• Analysis of HO-1/BVR-A pathway functions during MCI and AD progression.
FUNDINGs
2024 PI of The Project #2280 - GRT-2023B with the title “Nutrient-dependent alteration of the Unfolded Protein Response in Down syndrome brain: tackling the diet/cognition axis” funded by Jerome Lejeune Foundation with 80.000,00 Euro
2023 PI of the project prot. 2022KP5LKS with the title “The noxious crosstalk between protein O-GlcNAcylation and S-palmitoylation under metabolic stress: from their biochemical interaction to the development of neuropathological hallmarks” funded PRIN 2022 program of the Ministry of University and Research with 204.550,00 Euro
2022 Co-PI of the project MA12218162A911A3 with the title MUMAD: Multimode detection platform to Unravel molecular Mechanisms of Age-associated degenerative Disorders funded by the “progetti di Ateneo” program from Sapienza University of Rome with 48.036,00 Euro
2022 PI of the project RG12218162AE202C with the title “The noxious crosstalk between protein O-GlcNAcylation and S-palmitoylation under metabolic stress: from their biochemical interaction to the development of neuropathological hallmarks” funded by the “progetti di Ateneo” program from Sapienza University of Rome 73.890,00 Euro
2021 PI of the project RM12117A2EC1C9E4 with the title “Deciphering the the interplay between the unfolded protein response and insulin resistance in Down syndrome brain” funded by the “progetti di Ateneo” program from Sapienza University of Rome. 10.000,00 Euro
2019 PI of a project entitled “The sweet link between brain dys-metabolism and cognitive decline: A novel role for protein O-GlcNAcylation” funded by Pasteur Institute – Cenci Bolognetti Foundation under “Two year-research project reserved to under 45 years-old junior scientists” program 40.000,00 Euro
2019. Co-PI of the project GR-2018-12366381 with the title “Aberrant protein palmitoylation: a novel biomarker and therapeutic target in Alzheimer's disease” funded by Ministry of Health under BANDO RICERCA FINALIZZATA 2018 call. 422.000,00 Euro
2018. PI of the project RG1181642744DF59 with the title “The sweet link between aberrant brain metabolism and cognitive decline: A novel role for altered protein O-GlcNAcylation” funded by the “progetti di Ateneo” program from Sapienza University of Rome. 32.000,00 Euro
2017. PI of the project RM11715C773949E3 with the title “Inhibition of PERK pathway for the early treatment of Alzheimer Disease-like cognitive decline in Down Syndrome” funded by “progetti di Ateneo” program from Sapienza University of Rome. 31750,00 Euro
2016. PI of the project RG116154C9214D1A with the title “Brain insulin resistance in age-related cognitive decline: molecular mechanisms and novel therapeutic approaches” funded by the “progetti di Ateneo” program from Sapienza University of Rome. 34.000,00 Euro
2016. Co-PI of a project entitled “Novel therapeutic strategies for the prevention of Alzheimer Disease” funded by Banca D’Italia. 50.000,00 Euro
2016. Co-PI of project entitled “Intranasal rapamycin administration to prevent Alzheimer-like dementia in Down Syndrome”, funded by Jerome Lejeune foundation. 26.000,00 Euro
2015. PI of a project for Scientific Independent Research (SIR) program from Ministry of Instruction, University and Research (MIUR) Protocol #RBSI144MTL with the title “Cross-talk between insulin signalling and oxidative stress in Alzheimer disease: A new paradigm” 169.938,00 Euro
2013. Co-PI of Marie Curie action grant with the project “Biliverdin Reductase-A in brain insulin signaling and oxidative stress-mediated neurodegeneration” 180.000,00 Euro
2012. PI of a 1-year fellowship to hire a collaborator as one of the best young “under 40” researcher of faculty of pharmacy and medicine of Sapienza University of with the project “Role of oxidative stress in the mechanisms of neurodegeneration”. 22800,00 Euro

SOCIETY MEMBERBERSHIPS, AWARDS AND HONORS


2020 - present Editorial board member for the MDPI journal “NeuroSci” (ISSN 2673-4087)
2020 - present Invited guest editor for a special issue on “Feature paper in section Molecular Pathology” for “Biomolecules” (ISSN 2218-273X)
2019 - present Editorial board member for the MDPI journal “Biomolecules” (ISSN 2218-273X) section of Molecular Pathology
2015. Junior faculty award at 12th International Conference on Alzheimer’s Disease and Parkinson’s Disease (APDP 2015)
2013 – present. Member of Trisomy 21 research society T21RS
2012 - present . Member of Society of Free Radical Research – Europe (SFRRE)
2013. Associate editor of Journal of Alzheimer Disease – IOS press
2012. Selected among the best young “under 40” researcher of faculty of pharmacy and medicine of Sapienza University of Rome
2008 – present. Member of the Italian Society of Biochemistry and Molecular Biology (SIB)
LIST OF PUBLICATIONS
Book chapters
[1] F. Di Domenico, C. Lanzillotta. The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders. Advances in Protein Chemistry and Structural Biology, Academic Press, 2022, ISSN 1876-1623,
[2] M. Perluigi, F. Di Domenico. D. A. Butterfield. Oxidative stress and mTOR in Down syndrome brain: link to Alzheimer’s dysmetabolism, neuropathology and possible therapies. The neurobiology of aging and Alzheimer disease in Down syndrome. Academic Press. pp 75-96. ISBN 978-0-12-818845-3
[3] V. Calabrese, M. Perluigi, C. Cornelius, R. Coccia, F. Di Domenico, et al. (2009) Phenolics in aging and neurodegenerative disorders. Plant phenolics and human health. Wiley-IUBMB Series on Biochemistry and Molecular Biology. 427- 451
[4] F. Di Domenico, M. Perluigi. Peripheral Biomarkers of Oxidative Stress in Alzheimer’s Disease. Studies on Alzheimer's Disease. Humana Press, Editors: Domenico Praticὸ, Patrizia Mecocci, pp.185-199, DOI:10.1007/978-1-62703-598-9_13 ISBN: 978-1-62703-598-9
[5] F. Di Domenico, M. Perluigi, D.A. Butterfield. Redox proteomics in human biofluids: Sample preparation, separation and immunochemical tagging for analysis of protein oxidation. System Biology of Alzheimer’s Disease, pubs. August 02, 2015, pp. 391-403

International peer review journals

[1] C. Urbinati, C. Lanzillotta, L. Cosentino, D. Valenti, M.C. Quattrini, L. Di Crescenzo, F. Prestia, D. Pietraforte, M. Perluigi, F. Di Domenico, R.A. Vacca, B. De Filippis, Chronic treatment with the anti-diabetic drug metformin rescues impaired brain mitochondrial activity and selectively ameliorates defective cognitive flexibility in a female mouse model of Rett syndrome, Neuropharmacology 224 (2023) 109350.
[2] A. Tramutola, S. Lanzillotta, G. Aceto, S. Pagnotta, G. Ruffolo, P. Cifelli, F. Marini, C. Ripoli, E. Palma, C. Grassi, F. Di Domenico, M. Perluigi, E. Barone, Intranasal Administration of KYCCSRK Peptide Rescues Brain Insulin Signaling Activation and Reduces Alzheimer's Disease-like Neuropathology in a Mouse Model for Down Syndrome, Antioxidants (Basel) 12(1) (2023).
[3] F. Di Domenico, C. Lanzillotta, The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders, Adv Protein Chem Struct Biol 132 (2022) 49-87.
[4] S. Pagnotta, A. Tramutola, E. Barone, F. Di Domenico, V. Pittalà, L. Salerno, V. Folgiero, M. Caforio, F. Locatelli, S. Petrini, D.A. Butterfield,M. Perluigi, CAPE and its synthetic derivative VP961 restore BACH1/NRF2 axis in Down Syndrome Free Radical Biology and Medicine, 2022 in press
[5] M. Perluigi, A. Picca, E. Montanari, R. Calvani, F. Marini, R. Matassa, A. Tramutola, A.Villani, G. Familiari, F. Di Domenico, D.A. Butterfield, K.J. Oh, E. Marzetti, D. Valentini, E. Barone, Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronal-derived extracellular vesicles Alzheimer's and Dementia 2021 1-13.
[6] I. Zuliani, C. Lanzillotta, A. Tramutola, A. Francioso, S. Pagnotta, E. Barone, M. Perluigi, F. Di Domenico, The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome, Neurotherapeutics 18(1) (2021) 340-363.
[7] I. Zuliani, C. Lanzillotta, A. Tramutola, E. Barone, M. Perluigi, S. Rinaldo, A. Paone, F. Cutruzzola, F. Bellanti, M. Spinelli, F. Natale, S. Fusco, C. Grassi, F. Di Domenico, High-Fat Diet Leads to Reduced Protein O-GlcNAcylation and Mitochondrial Defects Promoting the Development of Alzheimer's Disease Signatures, Int J Mol Sci 22(7) (2021).
[8] M. Perluigi, F. Di Domenico, E. Barone, D.A. Butterfield, mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder, Free Radic Biol Med 169 (2021) 382-396.
[9] C. Lanzillotta, I. Zuliani, A. Tramutola, E. Barone, C. Blarzino, V. Folgiero, M. Caforio, D. Valentini, A. Villani, F. Locatelli, D.A. Butterfield, E. Head, M. Perluigi, J.F. Abisambra, F. Di Domenico, Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention, Prog Neurobiol 196 (2021) 101892.
[10] C. Lanzillotta, A. Tramutola, G. Di Giacomo, F. Marini, D.A. Butterfield, F. Di Domenico, M. Perluigi, E. Barone, Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome, Free Radic Biol Med 165 (2021) 152-170.
[11] C. Lanzillotta, F. Di Domenico, Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules, Biomolecules 11(2) (2021).
[12] S.A. Koren, M.J. Hamm, R. Cloyd, S.N. Fontaine, E. Chishti, C. Lanzillotta, J. Rodriguez-Rivera, A. Ingram, M. Bell, S.M. Galvis-Escobar, N. Zulia, F. Di Domenico, D. Duong, N.T. Seyfried, D. Powell, M. Vandsburger, T. Frolinger, A.M.S. Hartz, J. Koren, 3rd, J.M. Axten, N.J. Laping, J.F. Abisambra, Broad Kinase Inhibition Mitigates Early Neuronal Dysfunction in Tauopathy, Int J Mol Sci 22(3) (2021).
[13] D.J. Klionsky et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1), Autophagy 17(1) (2021) 1-382.
[14] E. Barone, F. Di Domenico, M. Perluigi, D.A. Butterfield, The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease, Free Radic Biol Med 176 (2021) 16-33.
[15] I. Zuliani, C. Urbinati, D. Valenti, M.C. Quattrini, V. Medici, L. Cosentino, D. Pietraforte, F. Di Domenico, M. Perluigi, R.A. Vacca, B. De Filippis, The Anti-Diabetic Drug Metformin Rescues Aberrant Mitochondrial Activity and Restrains Oxidative Stress in a Female Mouse Model of Rett Syndrome, J Clin Med 9(6) (2020).
[16] A. Tramutola, C. Lanzillotta, F. Di Domenico, E. Head, D.A. Butterfield, M. Perluigi, E. Barone, Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome, Neurobiol Dis 137 (2020) 104772.
[17] A. Tramutola, S. Falcucci, U. Brocco, F. Triani, C. Lanzillotta, M. Donati, C. Panetta, F. Luzi, F. Iavarone, F. Vincenzoni, M. Castagnola, M. Perluigi, F. Di Domenico, F. Marco, Protein Oxidative Damage in UV-Related Skin Cancer and Dysplastic Lesions Contributes to Neoplastic Promotion and Progression, Cancers (Basel) 12(1) (2020).
[18] V. Protto, A. Tramutola, M. Fabiani, M.E. Marcocci, G. Napoletani, F. Iavarone, F. Vincenzoni, M. Castagnola, M. Perluigi, F. Di Domenico, G. De Chiara, A.T. Palamara, Multiple Herpes Simplex Virus-1 (HSV-1) Reactivations Induce Protein Oxidative Damage in Mouse Brain: Novel Mechanisms for Alzheimer's Disease Progression, Microorganisms 8(7) (2020).
[19] C. Lanzillotta, I. Zuliani, C. Vasavda, S.H. Snyder, B.D. Paul, M. Perluigi, F. Di Domenico, E. Barone, BVR-A Deficiency Leads to Autophagy Impairment through the Dysregulation of AMPK/mTOR Axis in the Brain-Implications for Neurodegeneration, Antioxidants (Basel) 9(8) (2020).
[20] C. Lanzillotta, V. Greco, D. Valentini, A. Villani, V. Folgiero, M. Caforio, F. Locatelli, S. Pagnotta, E. Barone, A. Urbani, F. Di Domenico, M. Perluigi, Proteomics Study of Peripheral Blood Mononuclear Cells in Down Syndrome Children, Antioxidants (Basel) 9(11) (2020).
[21] N. Sharma, A. Tramutola, C. Lanzillotta, A. Arena, C. Blarzino, T. Cassano, D.A. Butterfield, F. Di Domenico, M. Perluigi, E. Barone, Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease, Neurobiol Dis 125 (2019) 176-189.
[22] C. Lanzillotta, F. Di Domenico, M. Perluigi, D.A. Butterfield, Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives, CNS Drugs 33(10) (2019) 957-969.
[23] F. Di Domenico, I. Zuliani, A. Tramutola, Shining a light on defective autophagy by proteomics approaches: implications for neurodegenerative illnesses, Expert Rev Proteomics 16(11-12) (2019) 951-964.
[24] F. Di Domenico, A. Tramutola, E. Barone, C. Lanzillotta, O. Defever, A. Arena, I. Zuliani, C. Foppoli, F. Iavarone, F. Vincenzoni, M. Castagnola, D.A. Butterfield, M. Perluigi, Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome, Redox Biol 23 (2019) 101162.
[25] F. Di Domenico, C. Lanzillotta, A. Tramutola, Therapeutic potential of rescuing protein O-GlcNAcylation in tau-related pathologies, Expert Rev Neurother 19(1) (2019) 1-3.
[26] F.A. Cimini, A. Arena, I. Barchetta, A. Tramutola, V. Ceccarelli, C. Lanzillotta, M. Fontana, L. Bertoccini, F. Leonetti, D. Capoccia, G. Silecchia, C. Di Cristofano, C. Chiappetta, F. Di Domenico, M.G. Baroni, M. Perluigi, M.G. Cavallo, E. Barone, Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity, Biochim Biophys Acta Mol Basis Dis 1865(6) (2019) 1490-1501.
[27] E. Barone, A. Tramutola, F. Triani, S. Calcagnini, F. Di Domenico, C. Ripoli, S. Gaetani, C. Grassi, D.A. Butterfield, T. Cassano, M. Perluigi, Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease, Mol Neurobiol 56(4) (2019) 2922-2943.
[28] F. Triani, A. Tramutola, F. Di Domenico, N. Sharma, D.A. Butterfield, E. Head, M. Perluigi, E. Barone, Biliverdin reductase-A impairment links brain insulin resistance with increased Abeta production in an animal model of aging: Implications for Alzheimer disease, Biochim Biophys Acta Mol Basis Dis 1864(10) (2018) 3181-3194.
[29] A. Tramutola, F. Triani, F. Di Domenico, E. Barone, J. Cai, J.B. Klein, M. Perluigi, D.A. Butterfield, Poly-ubiquitin profile in Alzheimer disease brain, Neurobiol Dis 118 (2018) 129-141.
[30] A. Tramutola, N. Sharma, E. Barone, C. Lanzillotta, A. Castellani, F. Iavarone, F. Vincenzoni, M. Castagnola, D.A. Butterfield, S. Gaetani, T. Cassano, M. Perluigi, F. Di Domenico, Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease, Biochim Biophys Acta Mol Basis Dis 1864(10) (2018) 3309-3321.
[31] A. Tramutola, C. Lanzillotta, E. Barone, A. Arena, I. Zuliani, L. Mosca, C. Blarzino, D.A. Butterfield, M. Perluigi, F. Di Domenico, Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome, Transl Neurodegener 7 (2018) 28.
[32] A. Tramutola, G. Abate, C. Lanzillotta, F. Triani, E. Barone, F. Iavarone, F. Vincenzoni, M. Castagnola, M. Marziano, M. Memo, E. Garrafa, D.A. Butterfield, M. Perluigi, F. Di Domenico, D. Uberti, Protein nitration profile of CD3(+) lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection, Free Radic Biol Med 129 (2018) 430-439.
[33] C. Lanzillotta, A. Tramutola, S. Meier, F. Schmitt, E. Barone, M. Perluigi, F. Di Domenico, J.F. Abisambra, Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models, J Alzheimers Dis 62(1) (2018) 347-359.
[34] F. Di Domenico, A. Tramutola, C. Foppoli, E. Head, M. Perluigi, D.A. Butterfield, mTOR in Down syndrome: Role in Ass and tau neuropathology and transition to Alzheimer disease-like dementia, Free Radic Biol Med 114 (2018) 94-101.
[35] A. Tramutola, C. Lanzillotta, F. Di Domenico, Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies, Expert Rev Neurother 17(1) (2017) 33-45.
[36] A. Tramutola, F. Di Domenico, E. Barone, A. Arena, A. Giorgi, L. di Francesco, M.E. Schinina, R. Coccia, E. Head, D.A. Butterfield, M. Perluigi, Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology, Antioxid Redox Signal 26(7) (2017) 280-298.
[37] S.N. Fontaine, A. Ingram, R.A. Cloyd, S.E. Meier, E. Miller, D. Lyons, G.K. Nation, E. Mechas, B. Weiss, C. Lanzillotta, F. Di Domenico, F. Schmitt, D.K. Powell, M. Vandsburger, J.F. Abisambra, Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach, Neurobiol Aging 56 (2017) 78-86.
[38] F. Di Domenico, A. Tramutola, D.A. Butterfield, Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders, Free Radic Biol Med 111 (2017) 253-261.
[39] F. Di Domenico, E. Barone, M. Perluigi, D.A. Butterfield, The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics, Antioxid Redox Signal 26(8) (2017) 364-387.
[40] A. Tramutola, G. Pupo, F. Di Domenico, E. Barone, A. Arena, C. Lanzillotta, D. Brokeaart, C. Blarzino, E. Head, D.A. Butterfield, M. Perluigi, Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype, J Alzheimers Dis 52(1) (2016) 359-371.
[41] A. Tramutola, C. Lanzillotta, A. Arena, E. Barone, M. Perluigi, F. Di Domenico, Increased Mammalian Target of Rapamycin Signaling Contributes to the Accumulation of Protein Oxidative Damage in a Mouse Model of Down's Syndrome, Neurodegener Dis 16(1-2) (2016) 62-8.
[42] A. Tramutola, F. Di Domenico, E. Barone, M. Perluigi, D.A. Butterfield, It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease, Oxid Med Cell Longev 2016 (2016) 2756068.
[43] C. Spadaccio, F. Nappi, N. Al-Attar, R. Coccia, M. Perluigi, F. Di Domenico, CURRENT DEVELOPMENTS IN DRUG ELUTING DEVICES: Introductory Editorial: Drug-Eluting Stents or Drug-Eluting Grafts? Insights from Proteomic Analysis, Drug Target Insights 10(Suppl 1) (2016) 15-19.
[44] C. Spadaccio, R. Coccia, M. Perluigi, G. Pupo, M.E. Schinina, A. Giorgi, C. Blarzino, F. Nappi, F.W. Sutherland, M. Chello, F. Di Domenico, Redox proteomic analysis of serum from aortic anerurysm patients: insights on oxidation of specific protein target, Mol Biosyst 12(7) (2016) 2168-77.
[45] M. Perluigi, E. Barone, F. Di Domenico, D.A. Butterfield, Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways, Biochim Biophys Acta 1862(10) (2016) 1871-82.
[46] D.J. Klionsky et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition), Autophagy 12(1) (2016) 1-222.
[47] F. Di Domenico, A. Tramutola, M. Perluigi, Cathepsin D as a therapeutic target in Alzheimer's disease, Expert Opin Ther Targets 20(12) (2016) 1393-1395.
[48] F. Di Domenico, G. Pupo, E. Giraldo, A. Lloret, M.C. Badia, M.E. Schinina, A. Giorgi, D.A. Butterfield, J. Vina, M. Perluigi, Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage, Curr Alzheimer Res 13(2) (2016) 112-22.
[49] F. Di Domenico, G. Pupo, E. Giraldo, M.C. Badia, P. Monllor, A. Lloret, M.E. Schinina, A. Giorgi, C. Cini, A. Tramutola, D.A. Butterfield, J. Vina, M. Perluigi, Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients, Free Radic Biol Med 91 (2016) 1-9.
[50] F. Di Domenico, M. Perluigi, D.A. Butterfield, Redox Proteomics in Human Biofluids: Sample Preparation, Separation and Immunochemical Tagging for Analysis of Protein Oxidation, Methods Mol Biol 1303 (2016) 391-403.
[51] E. Barone, F. Di Domenico, T. Cassano, A. Arena, A. Tramutola, M.A. Lavecchia, R. Coccia, D.A. Butterfield, M. Perluigi, Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm, Free Radic Biol Med 91 (2016) 127-42.
[52] A. Tramutola, J.C. Triplett, F. Di Domenico, D.M. Niedowicz, M.P. Murphy, R. Coccia, M. Perluigi, D.A. Butterfield, Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD, J Neurochem 133(5) (2015) 739-49.
[53] M. Perluigi, F. Di Domenico, D.A. Butterfield, mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy, Neurobiol Dis 84 (2015) 39-49.
[54] A. Nenna, F. Nappi, S.S. Avtaar Singh, F.W. Sutherland, F. Di Domenico, M. Chello, C. Spadaccio, Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease, Res Cardiovasc Med 4(2) (2015) e26949.
[55] F. Di Domenico, G. Pupo, C. Mancuso, E. Barone, F. Paolini, A. Arena, C. Blarzino, F.A. Schmitt, E. Head, D.A. Butterfield, M. Perluigi, Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease, J Alzheimers Dis 44(4) (2015) 1107-20.
[56] F. Di Domenico, E. Barone, M. Perluigi, D.A. Butterfield, Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants, Expert Rev Neurother 15(1) (2015) 19-40.
[57] G. Bedse, F. Di Domenico, G. Serviddio, T. Cassano, Aberrant insulin signaling in Alzheimer's disease: current knowledge, Front Neurosci 9 (2015) 204.
[58] E. Barone, G. Cenini, F. Di Domenico, T. Noel, C. Wang, M. Perluigi, D.K. St Clair, D.A. Butterfield, Basal brain oxidative and nitrative stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53, J Neurosci Res 93(11) (2015) 1728-39.
[59] C. Spadaccio, F. De Marco, F. Di Domenico, R. Coccia, M. Lusini, R. Barbato, E. Covino, M. Chello, Simvastatin attenuates the endothelial pro-thrombotic shift in saphenous vein grafts induced by Advanced glycation endproducts, Thromb Res 133(3) (2014) 418-25.
[60] M. Perluigi, G. Pupo, A. Tramutola, C. Cini, R. Coccia, E. Barone, E. Head, D.A. Butterfield, F. Di Domenico, Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain, Biochim Biophys Acta 1842(7) (2014) 1144-53.
[61] M. Perluigi, F. Di Domenico, D.A. Buttterfield, Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics, Proteomics Clin Appl 8(1-2) (2014) 73-85.
[62] F. Di Domenico, G. Pupo, A. Tramutola, A. Giorgi, M.E. Schinina, R. Coccia, E. Head, D.A. Butterfield, M. Perluigi, Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease, Free Radic Biol Med 71 (2014) 270-280.
[63] D.A. Butterfield, L. Gu, F. Di Domenico, R.A. Robinson, Mass spectrometry and redox proteomics: applications in disease, Mass Spectrom Rev 33(4) (2014) 277-301.
[64] D.A. Butterfield, F. Di Domenico, A.M. Swomley, E. Head, M. Perluigi, Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain, Biochem J 463(2) (2014) 177-89.
[65] D.A. Butterfield, F. Di Domenico, E. Barone, Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain, Biochim Biophys Acta 1842(9) (2014) 1693-706.
[66] E. Barone, F. Di Domenico, C. Mancuso, D.A. Butterfield, The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation, Neurobiol Dis 62 (2014) 144-59.
[67] E. Barone, F. Di Domenico, D.A. Butterfield, Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets, Biochem Pharmacol 88(4) (2014) 605-16.
[68] C. Spadaccio, G. Patti, F. De Marco, R. Coccia, F. Di Domenico, F. Pollari, R. Zanzonico, M. Pettinari, M. Lusini, G. Di Sciascio, E. Covino, M. Chello, Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study), Am J Cardiol 112(1) (2013) 21-6.
[69] A. Fiorini, T. Koudriavtseva, E. Bucaj, R. Coccia, C. Foppoli, A. Giorgi, M.E. Schinina, F. Di Domenico, F. De Marco, M. Perluigi, Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis, PLoS One 8(6) (2013) e65184.
[70] F. Di Domenico, M. Perluigi, E. Barone, Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain, Neural Regen Res 8(21) (2013) 1925-37.
[71] F. Di Domenico, F. De Marco, M. Perluigi, Proteomics strategies to analyze HPV-transformed cells: relevance to cervical cancer, Expert Rev Proteomics 10(5) (2013) 461-72.
[72] F. Di Domenico, R. Coccia, A. Cocciolo, M.P. Murphy, G. Cenini, E. Head, D.A. Butterfield, A. Giorgi, M.E. Schinina, C. Mancuso, C. Cini, M. Perluigi, Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain, Biochim Biophys Acta 1832(8) (2013) 1249-59.
[73] C. Spadaccio, F. Di Domenico, M. Perluigi, M. Lusini, A. Giorgi, M.E. Schinina, C. Blarzino, E. Covino, M. Chello, R. Coccia, Serum proteomics in patients with diagnosis of abdominal aortic aneurysm, Cardiovasc Pathol 21(4) (2012) 283-90.
[74] C. Mancuso, E. Barone, P. Guido, F. Miceli, F. Di Domenico, M. Perluigi, R. Santangelo, P. Preziosi, Inhibition of lipid peroxidation and protein oxidation by endogenous and exogenous antioxidants in rat brain microsomes in vitro, Neurosci Lett 518(2) (2012) 101-5.
[75] F. Di Domenico, R. Sultana, A. Ferree, K. Smith, E. Barone, M. Perluigi, R. Coccia, W. Pierce, J. Cai, C. Mancuso, R. Squillace, M. Wiengele, I. Dalle-Donne, B. Wolozin, D.A. Butterfield, Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease, Antioxid Redox Signal 17(11) (2012) 1490-506.
[76] F. Di Domenico, C. Foppoli, R. Coccia, M. Perluigi, Antioxidants in cervical cancer: chemopreventive and chemotherapeutic effects of polyphenols, Biochim Biophys Acta 1822(5) (2012) 737-47.
[77] F. Di Domenico, G. Casalena, J. Jia, R. Sultana, E. Barone, J. Cai, W.M. Pierce, C. Cini, C. Mancuso, M. Perluigi, C.M. Davis, N.J. Alkayed, D.A. Butterfield, Sex differences in brain proteomes of neuron-specific STAT3-null mice after cerebral ischemia/reperfusion, J Neurochem 121(4) (2012) 680-92.
[78] F. Di Domenico, E. Barone, C. Mancuso, M. Perluigi, A. Cocciolo, P. Mecocci, D.A. Butterfield, R. Coccia, HO-1/BVR-a system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease, J Alzheimers Dis 32(2) (2012) 277-89.
[79] F. De Marco, E. Bucaj, C. Foppoli, A. Fiorini, C. Blarzino, K. Filipi, A. Giorgi, M.E. Schinina, F. Di Domenico, R. Coccia, D.A. Butterfield, M. Perluigi, Oxidative stress in HPV-driven viral carcinogenesis: redox proteomics analysis of HPV-16 dysplastic and neoplastic tissues, PLoS One 7(3) (2012) e34366.
[80] A. Cocciolo, F. Di Domenico, R. Coccia, A. Fiorini, J. Cai, W.M. Pierce, P. Mecocci, D.A. Butterfield, M. Perluigi, Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics, Free Radic Biol Med 53(10) (2012) 1868-76.
[81] D.A. Butterfield, E. Barone, F. Di Domenico, G. Cenini, R. Sultana, M.P. Murphy, C. Mancuso, E. Head, Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain, Int J Neuropsychopharmacol 15(7) (2012) 981-7.
[82] E. Barone, C. Mancuso, F. Di Domenico, R. Sultana, M.P. Murphy, E. Head, D.A. Butterfield, Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease, J Neurochem 120(1) (2012) 135-46.
[83] E. Barone, F. Di Domenico, R. Sultana, R. Coccia, C. Mancuso, M. Perluigi, D.A. Butterfield, Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment, Free Radic Biol Med 52(11-12) (2012) 2292-301.
[84] E. Barone, G. Cenini, R. Sultana, F. Di Domenico, A. Fiorini, M. Perluigi, T. Noel, C. Wang, C. Mancuso, D.K. St Clair, D.A. Butterfield, Lack of p53 decreases basal oxidative stress levels in the brain through upregulation of thioredoxin-1, biliverdin reductase-A, manganese superoxide dismutase, and nuclear factor kappa-B, Antioxid Redox Signal 16(12) (2012) 1407-20.
[85] R. Sultana, R.A. Robinson, F. Di Domenico, H.M. Abdul, D.K. St Clair, W.R. Markesbery, J. Cai, W.M. Pierce, D.A. Butterfield, Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age, J Proteomics 74(11) (2011) 2430-40.
[86] M. Perluigi, F. di Domenico, A. Fiorini, A. Cocciolo, A. Giorgi, C. Foppoli, D.A. Butterfield, M. Giorlandino, C. Giorlandino, M.E. Schinina, R. Coccia, Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid, Proteomics Clin Appl 5(3-4) (2011) 167-78.
[87] F. Di Domenico, R. Sultana, E. Barone, M. Perluigi, C. Cini, C. Mancuso, J. Cai, W.M. Pierce, D.A. Butterfield, Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects, J Proteomics 74(7) (2011) 1091-103.
[88] F. Di Domenico, R. Coccia, D.A. Butterfield, M. Perluigi, Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits, Biochim Biophys Acta 1814(12) (2011) 1785-95.
[89] E. Barone, F. Di Domenico, G. Cenini, R. Sultana, R. Coccia, P. Preziosi, M. Perluigi, C. Mancuso, D.A. Butterfield, Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment, J Alzheimers Dis 25(4) (2011) 623-33.
[90] E. Barone, F. Di Domenico, G. Cenini, R. Sultana, C. Cini, P. Preziosi, M. Perluigi, C. Mancuso, D.A. Butterfield, Biliverdin reductase--a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment, Biochim Biophys Acta 1812(4) (2011) 480-7.
[91] E. Barone, G. Cenini, F. Di Domenico, S. Martin, R. Sultana, C. Mancuso, M.P. Murphy, E. Head, D.A. Butterfield, Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action, Pharmacol Res 63(3) (2011) 172-80.
[92] R. Sultana, F. Di Domenico, M. Tseng, J. Cai, T. Noel, R.L. Chelvarajan, W.D. Pierce, C. Cini, S. Bondada, D.K. St Clair, D.A. Butterfield, Doxorubicin-induced thymus senescence, J Proteome Res 9(12) (2010) 6232-41.
[93] M. Perluigi, F. Di Domenico, A. Giorgi, M.E. Schinina, R. Coccia, C. Cini, F. Bellia, M.T. Cambria, C. Cornelius, D.A. Butterfield, V. Calabrese, Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process, J Neurosci Res 88(16) (2010) 3498-507.
[94] M. Perluigi, F. Di Domenico, C. Blarzino, C. Foppoli, C. Cini, A. Giorgi, C. Grillo, F. De Marco, D.A. Butterfield, M.E. Schinina, R. Coccia, Effects of UVB-induced oxidative stress on protein expression and specific protein oxidation in normal human epithelial keratinocytes: a proteomic approach, Proteome Sci 8 (2010) 13.
[95] F. Di Domenico, R. Sultana, G.F. Tiu, N.N. Scheff, M. Perluigi, C. Cini, D.A. Butterfield, Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease, Brain Res 1333 (2010) 72-81.
[96] F. Di Domenico, M. Perluigi, D.A. Butterfield, C. Cornelius, V. Calabrese, Oxidative damage in rat brain during aging: interplay between energy and metabolic key target proteins, Neurochem Res 35(12) (2010) 2184-92.
[97] F. Di Domenico, J.B. Owen, R. Sultana, R.A. Sowell, M. Perluigi, C. Cini, J. Cai, W.M. Pierce, D.A. Butterfield, The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression, J Neurosci Res 88(16) (2010) 3566-77.
[98] F. Di Domenico, G. Casalena, R. Sultana, J. Cai, W.M. Pierce, M. Perluigi, C. Cini, A. Baracca, G. Solaini, G. Lenaz, J. Jia, S. Dziennis, S.J. Murphy, N.J. Alkayed, D.A. Butterfield, Involvement of Stat3 in mouse brain development and sexual dimorphism: a proteomics approach, Brain Res 1362 (2010) 1-12.
[99] M. Perluigi, R. Sultana, G. Cenini, F. Di Domenico, M. Memo, W.M. Pierce, R. Coccia, D.A. Butterfield, Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis, Proteomics Clin Appl 3(6) (2009) 682-693.
[100] M. Perluigi, A. Giorgi, C. Blarzino, F. De Marco, C. Foppoli, F. Di Domenico, D.A. Butterfield, M.E. Schinina, C. Cini, R. Coccia, Proteomics analysis of protein expression and specific protein oxidation in human papillomavirus transformed keratinocytes upon UVB irradiation, J Cell Mol Med 13(8B) (2009) 1809-1822.
[101] M. Perluigi, F. Di Domenico, C. Cini, R. Coccia, F.R. Giorlandino, M. Giorlandino, P. Cignini, A. Mesoraca, C. Giorlandino, Proteomic analysis for the study of amniotic fluid protein composition, J Prenat Med 3(3) (2009) 39-41.
[102] J.B. Owen, F. Di Domenico, R. Sultana, M. Perluigi, C. Cini, W.M. Pierce, D.A. Butterfield, Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD, J Proteome Res 8(2) (2009) 471-82.
[103] F. Di Domenico, M. Perluigi, C. Foppoli, C. Blarzino, R. Coccia, F. De Marco, D.A. Butterfield, C. Cini, Protective effect of ferulic acid ethyl ester against oxidative stress mediated by UVB irradiation in human epidermal melanocytes, Free Radic Res 43(4) (2009) 365-75.
[104] F. Di Domenico, C. Foppoli, C. Blarzino, M. Perluigi, F. Paolini, S. Morici, R. Coccia, C. Cini, F. De Marco, Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity, J Exp Clin Cancer Res 28 (2009) 4.
[105] F. Di Domenico, G. Cenini, R. Sultana, M. Perluigi, D. Uberti, M. Memo, D.A. Butterfield, Glutathionylation of the pro-apoptotic protein p53 in Alzheimer's disease brain: implications for AD pathogenesis, Neurochem Res 34(4) (2009) 727-33.
[106] M. Chello, C. Spadaccio, M. Lusini, E. Covino, C. Blarzino, F. De Marco, F. Di Domenico, R. Coccia, Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure, Diabetes Metab Res Rev 25(5) (2009) 420-6.